Topics

A research group Senior Staff by Professor Kozuma has revealed that short-term combination therapy with antithrombotic drugs does not increase the risk of thrombosis-related complications.

A research group led by Professor Ken Uezuma, Senior Staff the Department of Clinical Medicine and Internal Medicine at Teikyo University School of Medicine, has revealed that in patients with coronary artery disease and atrial fibrillation, shortening the combination of two antithrombotic drugs from 12 months to 1 month after coronary artery stenting (PCI) does not increase the incidence of thrombosis-related complications and reduces the occurrence of bleeding.

This study was conducted as the "OPTIMA-AF trial," a randomized controlled trial involving 75 facilities across Japan, and investigated the safety and efficacy of shortening the treatment period in 1088 patients. Previously, a challenge in antithrombotic therapy after PCI in patients with atrial fibrillation was the increased risk of bleeding. This study suggests that shortening the duration of drug use may allow for safer treatment.
The results of this research were published in the American scientific journal "The Lancet" on July 16, 2026 (Thursday).

The press release is available here.
Senior Staff here for information about Professor Uezuma.

To the topic List